Should I Buy REPL? REPL 2026 Analysis

Should You Buy Replimune Group Inc (REPL) Today? Analysis, Price Targets, and 2026 Outlook.

Conclusion

Hold

Latest Price

7.390

1 Day change

0.41%

52 Week Range

14.800

Analysis Updated At

2026/01/26

Replimune Group Inc (REPL) is not a strong buy at the moment for a beginner, long-term investor with $50,000-$100,000 available for investment. While there is a positive pre-market price change and an analyst upgrade, the technical indicators, financial performance, and lack of significant trading signals suggest a cautious approach. Holding off for now and monitoring further developments is recommended.

Technical Analysis

The MACD is below 0 and negatively contracting, indicating bearish momentum. RSI is neutral at 47.01, and moving averages are converging, showing no clear trend. The stock is trading near its pivot level of 7.642, with resistance at 8.32 and support at 6.964.

Options Data

Bullish

Open Interest Put-Call Ratio

Bullish

Option Volume Put-Call Ratio

Technical Summary

Sell

Buy

Positive Catalysts

BMO Capital upgraded the stock from Underperform to Market Perform, raising the price target from $2 to $11, citing better alignment with regulators and a productive Type A meeting supporting potential approval of the RP1 program.

Neutral/Negative Catalysts

No significant hedge fund or insider trading trends. The financial performance shows no revenue growth, and the company remains unprofitable with a net income of -$83.1M. Technical indicators do not show strong bullish signals.

Financial Performance

In Q2 2026, revenue remained at $0 with no YoY growth. Net income improved by 56.63% YoY but remains negative at -$83.1M. EPS increased by 32.35% YoY to -0.9, but the company is still operating at a loss.

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

BMO Capital upgraded the stock to Market Perform from Underperform and raised the price target to $11, reflecting improved regulatory alignment and potential approval of the RP1 program.

7 Analyst Rating

Wall Street analysts forecast REPL stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for REPL is 11.43 USD with a low forecast of 3 USD and a high forecast of 18 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

4 Buy

3 Hold

0 Sell

Moderate Buy

Current: 7.360

Low

Averages

11.43

High

Current: 7.360

Low

Averages

11.43

High

BMO Capital

Evan Seigerman

Underperform

Market Perform

upgrade

$2 -> $11

AI Analysis

2025-11-03

Reason

BMO Capital

Evan Seigerman

Price Target

$2 -> $11

AI Analysis

2025-11-03

upgrade

Underperform

Market Perform

Reason

BMO Capital analyst Evan Seigerman upgraded Replimune to Market Perform from Underperform with a price target of $11, up from $2. The firm says current share levels "reflect appropriate risk" for the company's RP1 program. Replimune seems to have better alignment with regulators on a path forward for the drug, the analyst tells investors in a research note. BMO says Replimune's "productive" Type A meeting supports potential approval.

H.C. Wainwright

Neutral -> Buy

upgrade

$12

2025-10-27

Reason

H.C. Wainwright

Price Target

$12

2025-10-27

upgrade

Neutral -> Buy

Reason

H.C. Wainwright upgraded Replimune to Buy from Neutral with a $12 price target after the company resubmitted the biologics license application for RP1 plus Opdivo for the treatment of adult patients with advanced melanoma who have previously received an anti-PD1 containing regimen. The firm increased its probability of approval of RP1 plus Opdivo in anti-PD1 failed melanoma patients to 85% from 50%. The FDA indicated that this resubmission is considered a comprehensive response to the complete response letter received in July, the analyst tells investors in a research note.

Unlock Full Analyst Thesis， Get the complete breakdown of rating reason for REPL

Unlock Now

REPL Should I Buy

REPL Should I Buy

Should You Buy Replimune Group Inc (REPL) Today? Analysis, Price Targets, and 2026 Outlook.

Technical Analysis

Options Data

Technical Summary

Positive Catalysts

Neutral/Negative Catalysts

Financial Performance

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

People Also Watch